Search results for "harm"

showing 10 items of 13866 documents

Effects of Sulpiride Treatment on the Hypothalamic Supraoptic and Paraventricular Nuclei

2009

medicine.medical_specialtySettore BIO/16 - Anatomia Umanabusiness.industrymedia_common.quotation_subjectGeneral MedicinePharmacologySulpiridehypothalamic supraoptic nucleushypothalamic paraventricular nucleusmenstrual cyclePharmacotherapyEndocrinologyHypothalamusInternal medicinePharmacodynamicsmedicineSulpiridebusinessMenstrual cycleDepression (differential diagnoses)media_commonmedicine.drugResearch Journal of Biological Sciences
researchProduct

Treatment strategies for cancer patients with breakthrough pain.

2009

Breakthrough pain (BTP) is a transitory flare of pain superimposed on an otherwise stable pain pattern in patients treated with opioids. It is normally severe in intensity, has a rapid onset, has a variable duration (on average 30 min) and is considered a negative prognostic factor. OBJECTIVE: To verify the data in the literature about therapy strategies for BTP in cancer patients. METHODS: To find clinical trials investigating drug therapy for BTP. CONCLUSION: The treatment of BTP in cancer patients receiving opioids is principally based on the use of opioids, preferentially with a short onset. Fentanyl delivered by recently developed systems seems to be the best option to cover the tempor…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaBreakthrough PainPainFentanylPharmacotherapyNeoplasmsInternal medicinemedicineAnimalsHumansPharmacology (medical)In patientPain MeasurementPharmacologybusiness.industryCancerGeneral Medicinemedicine.diseaseAnalgesics OpioidFentanylClinical trialTreatment OutcomeAnesthesiaTreatment strategycancer pain opiods breakthrough painbusinessCancer painmedicine.drug
researchProduct

Adherence, compliance and persistence to oral antineoplastic therapy: a review focused on chemotherapeutic and biologic agents

2011

Introduction: To date, orally administered chemotherapy and biologic agents represent a significant percentage of all antineoplastic treatments in several types of cancer, which are most likely to increase in the near future. In this scenario, the issue of adherence and persistence to oral therapy is a key issue since poor compliance to oral antineoplastic treatments may negatively influence patients' clinical outcomes and, in turn, cause an increase in costs, number of hospitalizations and time spent in the hospital. Areas covered: The issue of adherence to new oral chemotherapeutic and/or biologic agents has not been deeply evaluated and data published in medical literature are quite scar…

medicine.medical_specialtySettore MED/06 - Oncologia MedicaPoor compliancemedicine.medical_treatmentAdministration OralAntineoplastic AgentsPharmacologySocioeconomic FactorMedication AdherencePersistence (computer science)PersistenceAntineoplastic AgentImmunologic FactorNeoplasmsHumansImmunologic FactorsMedicinePharmacology (medical)Intensive care medicineOral therapyCancerChemotherapybusiness.industryCancerHealth Care CostsGeneral MedicineDrug adherencemedicine.diseaseBiologic AgentsHealth Care CostHospitalizationSocioeconomic FactorsAdherenceNeoplasmbusinessOral chemotherapyHumanMedical literatureExpert Opinion on Drug Safety
researchProduct

Is 5-ASA Still the Treatment of Choice for Ulcerative Colitis?

2010

5-Amino-salacylic acid (5-ASA) is up to now the treatment of choice in the induction and maintenance of remission of mild-to-moderate ulcerative colitis (UC). Sulfasalazine, despite similar efficacy, is hampered by more side effects, but in presence of peripheral arthopaties it remains the treatment of choice. The new delayed release MMX formulation seems to be promising in reducing compliance problems, but further studies are warranted to show the superiority of new MMX formulation compared with the older formulations of 5-ASA. Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to ther…

medicine.medical_specialtySettore MED/09 - Medicina InternaClinical BiochemistryPharmacologyPlaceboSulfasalazineInternal medicineDrug DiscoverymedicineHumansDosingColitisMesalamine5-ASA Treatment Choice Ulcerative ColitisPharmacologyClinical Trials as Topicbusiness.industryAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseUlcerative colitisTacrolimusRegimenMolecular MedicineColitis UlcerativeRosiglitazonebusinessmedicine.drugCurrent Drug Targets
researchProduct

Antiplatelets in stroke prevention

2014

Stroke is the second cause of death worldwide and one of the leading cause of disability. Due to the high rate of recurrence, in high risk-patients (eg patients affected by atherosclerotic vascular disease), long-term antiplatelet therapy reduces the risk of vascular events such as non-fatal myocardial infarction, non-fatal stroke, or vascular death. The percentage of reduction of the events can be estimated in approximately 25%. These data justify the directions that are given to us by the current guidelines for prevention of secondary stroke, which recommend the broad use of antiplatelet therapy both for the secondary prevention of stroke in patients with a history of non-cardioembolic st…

medicine.medical_specialtySettore MED/09 - Medicina InternaMEDLINEPrimary preventionSecondary PreventionmedicineAnimalsHumanscardiovascular diseasesMyocardial infarctionIntensive care medicineStrokeCause of deathPharmacologySecondary preventionAspirinAspirinbusiness.industrymedicine.diseasePrimary PreventionStrokeCardiovascular DiseasesPhysical therapyPlatelet aggregation inhibitorantiplatelets Stroke preventionCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retr…

2021

Abstract Background Homozygous familial hypercholesterolemia (HoFH) is a rare life-threatening condition that represents a therapeutic challenge. The vast majority of HoFH patients fail to achieve LDL-C targets when treated with the standard protocol, which associates maximally tolerated dose of lipid-lowering medications with lipoprotein apheresis (LA). Lomitapide is an emerging therapy in HoFH, but its place in the treatment algorithm is disputed because a comparison of its long-term efficacy versus LA in reducing LDL-C burden is not available. We assessed changes in long-term LDL-C burden and goals achievement in two independent HoFH patients’ cohorts, one treated with lomitapide in Ita…

medicine.medical_specialtySettore MED/09 - Medicina Interna[SDV]Life Sciences [q-bio]LipoproteinsGenetic diseaseTherapeuticsFamilial hypercholesterolemiaDiseaseLipoprotein apheresiLDLHyperlipoproteinemia Type IIchemistry.chemical_compoundLipoprotein apheresisRetrospective surveyInternal medicineCholesterol burden; Genetic disease; Homozygous hypercholesterolemia; LDL; Lipoprotein apheresis; Lomitapide; Therapeutics; Benzimidazoles; Homozygote; Humans; Lipoproteins; Retrospective Studies; Anticholesteremic Agents; Blood Component Removal; Hyperlipoproteinemia Type IImedicineHumansPharmacology (medical)Genetics (clinical)Retrospective Studiesmedicine.diagnostic_testbusiness.industryResearchAnticholesteremic AgentsHomozygous hypercholesterolemiaHomozygoteRGeneral Medicinemedicine.diseaseLomitapideLomitapidecholesterol burden; genetic disease; homozygous hypercholesterolemia; LDL; lipoprotein apheresis; lomitapide; therapeuticsCholesterol burdenchemistryCohortBlood Component RemovalMedicineTherapeutics.BenzimidazolesLipid profilebusinessLipoprotein apheresisCross nationalOrphanet Journal of Rare Diseases
researchProduct

Investigation and management of Toxoplasma gondii infection in pregnancy and infancy: a prospective study.

2011

Aim:Toxoplasma gondii infection during pregnancy poses a serious risk to the fetus, therefore timely and accurate diagnosis is essential. The aim of this study was to estimate the frequency of congenital infection via evaluating mother's immunological status and the possibility to improving the diagnostic and therapeutic approaches.Methods:Eighty five mothers with Toxoplasma seroconversion and their offspring were enrolled (among them, 2 spontaneous abortions were documented in the first trimester). Prenatal PCR diagnosis was carried out on 50 patients (60%), with 7 positive cases (14%). Morphological ultrasound scanning revealed anomalies in one fetus. Long-term follow-up included general …

medicine.medical_specialtySettore MED/17 - Malattie InfettiveOffspringToxoplasmosis gondiineurological prognosiToxoplasmosis CongenitalSerologySettore MED/38 - Pediatria Generale E SpecialisticaPregnancyPrenatal DiagnosismedicineHumansPharmacology (medical)Prospective StudiesSeroconversionProspective cohort studyChildPharmacologyFetusPregnancybiologybusiness.industryObstetricsSettore MED/30 - Malattie Apparato Visivoocular prognosiPregnancy OutcomeToxoplasma gondiiGeneral Medicinemedicine.diseasebiology.organism_classificationToxoplasmosisInfectious Disease Transmission Verticalcongenital infectionWestern blot analysisprenatal screeningChild PreschoolPregnancy Complications ParasiticImmunologyserological responseFemaleOriginal ArticlebusinessFollow-Up StudiesActa pharmacologica Sinica
researchProduct

miRNA-23b as a biomarker of culture-positive neonatal sepsis

2020

Abstract Background Neonatal sepsis remains an important cause of morbidity and mortality. The ability to quickly and accurately diagnose neonatal sepsis based on clinical assessments and laboratory blood tests remains difficult, where haemoculture is the gold standard for detecting bacterial sepsis in blood culture. It is also very difficult to study because neonatal samples are lacking. Methods Forty-eight newborns suspected of sepsis admitted to the Neonatology Department of the Mother-Child Specialized Hospital of Tlemcen. From each newborn, a minimum of 1–2 ml of blood was drawn by standard sterile procedures for blood culture. The miRNA-23b level in haemoculture was evaluated by RT-qP…

medicine.medical_specialtyShort ReportEarly-onset sepsisGastroenterologylcsh:BiochemistrySepsisInternal medicinemicroRNAGeneticsmedicinelcsh:QD415-436Blood cultureNeonatologyMolecular BiologyGenetics (clinical)miR-23bNewbornsHaemocultureNeonatal sepsismedicine.diagnostic_testbusiness.industrylcsh:RM1-950Gold standardLate-onset sepsismedicine.diseaseMolecular medicinelcsh:Therapeutics. PharmacologyMolecular MedicineBiomarker (medicine)businessMolecular Medicine
researchProduct

Impact of depressive symptoms on subjective well-being: the importance of patient-reported outcomes in schizophrenia

2011

Jorge Mauriño1, Julio Sanjúan2, Josep Maria Haro3, Teresa Díez1, Javier Ballesteros41AstraZeneca Medical Department, Madrid, Spain; 2Department of Psychiatry, University of Valencia, CIBERSAM, Valencia, Spain; 3Parc Sanitari Sant Joan de Deu, CIBERSAM, Sant Boi de Llobregat, Spain; 4Department of Neuroscience-Psychiatry, University of the Basque Country, UPV/EHU, CIBERSAM, Leioa, SpainObjective: The subjective experience of psychotic patients toward treatment is a key factor in medication adherence, quality of life, and clinical outcome. The aim of this study was to assess the subjective well-being in patients with schizophrenia and to examine its relationsh…

medicine.medical_specialtyShort ReportPHARMACOLOGY TOXICOLOGY AND PHARMACEUTICSMedicine (miscellaneous)patient-reported outcomeCorrelationdepressive symptomsSOCIAL SCIENCESQuality of lifeInternal medicineHEALTH POLICY AND SERVICESMedicineSubjective well-beingPsychiatryPharmacology Toxicology and Pharmaceutics (miscellaneous)Depressive symptomsRank correlationMEDICINEbusiness.industryHealth PolicyArea under the curvemedicine.diseaseschizophreniapatient reported outcomesubjective well beingsubjective well-beingPatient Preference and AdherenceSchizophreniaPatient-reported outcomebusinessSocial Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental s…

2016

We have reviewed the safety and tolerability of β3-adrenoceptor agonists, specifically mirabegron and solabegron, a newly emerging drug class for the treatment of the overactive bladder syndrome. We discuss them mechanistically in the context of expression and other preclinical data.Based on a systematic PubMed search, incidence of overall adverse events, hypertension, dry mouth, and constipation are comparable between mirabegron or solabegron and placebo. Hypertension is the most frequently observed adverse event, but has a similar incidence with mirabegron and placebo. Nevertheless, severe uncontrolled hypertension has become a contraindication for use of mirabegron based on observation o…

medicine.medical_specialtySide effect030232 urology & nephrologyUrologyContext (language use)Adrenergic beta-3 Receptor AgonistsBenzoates03 medical and health sciences0302 clinical medicineSolabegronmedicineAnimalsHumansPharmacology (medical)Adverse effectAniline Compoundsbusiness.industryUrinary Bladder OveractiveGene Expression ProfilingBiphenyl CompoundsGeneral MedicineBiphenyl compoundThiazolesTolerability030220 oncology & carcinogenesisAnesthesiaReceptors Adrenergic beta-3AcetanilidesTolterodinebusinessMirabegronmedicine.drugExpert opinion on drug safety
researchProduct